LifeVantage (LFVN) AI Stock Analysis

• Market Cap: $82.56M
• Dividend Yield: 2.71%
• Average Volume (3M): 173.22K
• Price to Earnings (P/E): 8.4
• Beta (1Y): -0.03
• Revenue Growth: 16.77%
• EPS Growth: 143.30%
• Country: US
• Employees: 222
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Packaged Foods
• EPS (TTM): 0.17
• Shares Outstanding: 12,701,187
• 10 Day Avg. Volume: 145,627
• 30 Day Avg. Volume: 173,223
• PEG Ratio: 0.07
• Price to Book (P/B): 4.63
• Price to Sales (P/S): 0.70
• P/FCF Ratio: 15.25
• Enterprise Value/Market Cap: 1.50
• Enterprise Value/Revenue: 0.52
• Enterprise Value/Gross Profit: 0.64
• Enterprise Value/Ebitda: 7.31
• 1Y Price Target: $12.00
• Price Target Upside: 77.51% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 1.05
• Revenue Forecast (FY): $227.51M

• Rating: 66 Neutral
• Price Target: $7.00 ▲(3.55% Upside)

LifeVantage's overall stock score reflects a mix of strong financial performance and attractive valuation, offset by bearish technical indicators and some operational challenges highlighted in the earnings call. The company's strategic initiatives, particularly in the gut health market, provide a positive outlook, but maintaining operational efficiency and addressing cost pressures will be key to future success.

Positive Factors

Strategic Acquisition

The acquisition of LoveBiome positions LifeVantage in the fast-growing gut health segment, potentially driving long-term revenue growth as the market is projected to expand significantly by 2035.

Technological Advancements

The partnership with Shopify for a new e-commerce platform is expected to enhance LifeVantage's market reach and operational efficiency, supporting sustainable growth.

Strong Cash Position

Having a strong cash position and no debt provides LifeVantage with financial flexibility to invest in growth opportunities and weather economic uncertainties.

Negative Factors

Decline in Adjusted EBITDA

The decline in adjusted EBITDA indicates pressure on profitability due to lower gross margins and higher expenses, which could impact long-term financial performance if not addressed.

Lower Contribution Margin

A lower contribution margin suggests challenges in maintaining cost efficiency, which could affect LifeVantage's ability to sustain profit margins over time.

Increased Costs

Rising costs, particularly in logistics, may erode profitability if not managed effectively, posing a risk to LifeVantage's long-term margin sustainability.

LifeVantage Business Overview & Revenue Model

Company Description

LifeVantage Corporation (LFVN) is a biotechnology company that specializes in developing and marketing nutritional supplements and skincare products. The company focuses on products that promote health and wellness through activating the body’s natural defense systems. LifeVantage operates primarily in the health and wellness sector and is known for its flagship products, including Protandim, a dietary supplement that claims to reduce oxidative stress, and a range of skin care products that leverage the science of NRF2 activation.

How the Company Makes Money

LifeVantage generates revenue primarily through direct sales of its products, utilizing a multi-level marketing (MLM) business model. Independent distributors sell LifeVantage products directly to consumers and earn commissions based on their sales and the sales made by their recruited team members. This creates a tiered compensation structure that incentivizes recruitment and sales. Key revenue streams include product sales, distributor fees, and commissions from the MLM structure. Additionally, the company may engage in partnerships with other health and wellness brands or distributors to expand its market reach and enhance its product offerings, further contributing to its earnings.

LifeVantage Financial Statement Overview

Summary

LifeVantage demonstrates solid financial performance with strong profitability and improved revenue growth. The balance sheet reflects a healthy capital structure with reduced debt levels. Cash flow generation is robust, although recent declines in free cash flow warrant attention. Overall, the company is well-positioned for future growth, but maintaining operational efficiency and cash flow stability will be crucial.

Income Statement

LifeVantage shows a strong gross profit margin of over 80% in TTM, indicating efficient cost management. The net profit margin has improved to 4.43% in TTM, reflecting better profitability. Revenue growth is positive at 15.2% in TTM, a significant improvement from previous periods. However, EBIT and EBITDA margins have slightly decreased in TTM, suggesting some pressure on operational efficiency.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.34 in TTM, indicating a lower reliance on debt financing. Return on equity is strong at 31.07% in TTM, showing effective use of equity to generate profits. The equity ratio is stable, reflecting a balanced capital structure. However, the total assets have decreased slightly, which could limit future growth potential.

Cash Flow

Operating cash flow to net income ratio is healthy at 0.54 in TTM, indicating good cash generation relative to net income. However, free cash flow has declined by 17.25% in TTM, which could impact future investments. The free cash flow to net income ratio remains strong at 0.86, suggesting efficient cash utilization despite the decline.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	239.76M	228.53M	200.16M	213.40M	206.36M	220.18M
Gross Profit	193.27M	183.67M	158.72M	170.01M	168.26M	181.99M
EBITDA	16.97M	15.36M	7.91M	7.84M	7.96M	21.07M
Net Income	11.45M	9.80M	2.94M	2.54M	3.12M	12.89M
Balance Sheet
Total Assets	61.58M	71.96M	60.30M	66.12M	70.71M	78.73M
Cash, Cash Equivalents and Short-Term Investments	13.09M	20.20M	16.89M	21.61M	20.19M	23.17M
Total Debt	11.19M	11.68M	13.61M	13.09M	15.76M	18.18M
Total Liabilities	28.42M	37.32M	34.31M	31.47M	39.19M	41.92M
Stockholders Equity	33.16M	34.64M	25.99M	34.65M	31.52M	36.81M
Cash Flow
Free Cash Flow	8.70M	10.51M	10.51M	3.76M	3.76M	12.53M
Operating Cash Flow	10.16M	11.88M	11.88M	6.83M	6.83M	16.27M
Investing Cash Flow	-1.46M	-1.37M	-1.37M	-3.06M	-3.06M	-3.73M
Financing Cash Flow	-10.07M	-7.60M	-7.60M	-2.36M	-2.36M	-11.45M

LifeVantage Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.76
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFVN, the sentiment is Negative. The current price of 6.76 is above the 20-day moving average (MA) of 6.57, below the 50-day MA of 7.50, and below the 200-day MA of 11.58, indicating a bearish trend. The MACD of -0.26 indicates Negative momentum. The RSI at 39.26 is Neutral, neither overbought nor oversold. The STOCH value of 18.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LFVN.

LifeVantage Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NATR	80 Outperform	$397.85M	28.63	9.52%	―	6.62%	-7.85%
HLF	71 Outperform	$1.52B	4.76	―	―	-0.78%	265.56%
LFVN	66 Neutral	$82.56M	8.44	33.31%	2.71%	16.77%	143.30%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
USNA	61 Neutral	$373.48M	22.83	3.20%	―	5.88%	-68.62%
HAIN	38 Underperform	$101.44M	-0.20	-75.51%	―	-10.13%	-532.32%

LifeVantage Corporate Events

LifeVantage Holds Annual Stockholders Meeting, Elects Directors

LifeVantage Corporation held its fiscal year 2026 annual meeting of stockholders on November 6, 2025, where 75.41% of the company’s common stock was represented. During the meeting, stockholders elected seven directors to the board, approved executive compensation on an advisory basis, ratified Deloitte & Touche as the independent accounting firm, and approved an amendment to the 2017 Long-Term Incentive Plan.